IgAN annual incidence and 2021 expected incident cases in pediatric patients in European countries, based on national kidney biopsy registry data (and regional data for Germany) (Estimate 2: pediatric patients).
| Country . | Registry . | Time frame . | Number of native kidney biopsies in pediatric patients . | Pediatric age group definition . | Annual IgAN incidence per 100 000 pediatric patients . | Pediatric population in 2021a . | Expected incident IgAN cases in pediatric patients in 2021b . |
|---|---|---|---|---|---|---|---|
| Croatia [32] | Registry of Biopsy-Proven Renal Diseases | 1991–2004 | 565 | 0–17 | 0.51c | 716 172 | 4 |
| Czech Republic [14] | Czech Registry of Renal Biopsies | 1994–2011 | 1421 | 0–15 | 0.78c | 1 721 898 | 13 |
| Estonia [16] | Tartu University Hospital | 2001–2010 | 13d | 0–15 | 0.00 | 209 330 | 0 |
| Germany [33] | University Hospital Aachen | 1990–2013 | 23 | 0–15 | 0.19c | 11 037 903 | 21e |
| Lithuania [18] | National Center of Pathology | 2007–2012 | 114 | 0–16f | 0.79c | 467 450 | 4 |
| Poland | |||||||
| [20] | Polish Registry of Renal Biopsies | 2009–2014 | 384 | 0–17 | 0.18c | 6 706 811 | 12 |
| [34] | Polish pediatric IgAN registry | 2000–2015 | 140g | 0–17 | 0.16 | 11 | |
| Spain [35] | Spanish Registry of Glomerulonephritis | 2010–2013 | 238h | 0–16 | 0.03c | 7 913 453 | 2 |
| Pooled (incl. Germany) | – | – | – | – | 0.19i | 28 773 017 | 56j |
| Pooled (excl. Germany) | – | – | – | – | 0.20i | 17 735 114 | 35j |
| Country . | Registry . | Time frame . | Number of native kidney biopsies in pediatric patients . | Pediatric age group definition . | Annual IgAN incidence per 100 000 pediatric patients . | Pediatric population in 2021a . | Expected incident IgAN cases in pediatric patients in 2021b . |
|---|---|---|---|---|---|---|---|
| Croatia [32] | Registry of Biopsy-Proven Renal Diseases | 1991–2004 | 565 | 0–17 | 0.51c | 716 172 | 4 |
| Czech Republic [14] | Czech Registry of Renal Biopsies | 1994–2011 | 1421 | 0–15 | 0.78c | 1 721 898 | 13 |
| Estonia [16] | Tartu University Hospital | 2001–2010 | 13d | 0–15 | 0.00 | 209 330 | 0 |
| Germany [33] | University Hospital Aachen | 1990–2013 | 23 | 0–15 | 0.19c | 11 037 903 | 21e |
| Lithuania [18] | National Center of Pathology | 2007–2012 | 114 | 0–16f | 0.79c | 467 450 | 4 |
| Poland | |||||||
| [20] | Polish Registry of Renal Biopsies | 2009–2014 | 384 | 0–17 | 0.18c | 6 706 811 | 12 |
| [34] | Polish pediatric IgAN registry | 2000–2015 | 140g | 0–17 | 0.16 | 11 | |
| Spain [35] | Spanish Registry of Glomerulonephritis | 2010–2013 | 238h | 0–16 | 0.03c | 7 913 453 | 2 |
| Pooled (incl. Germany) | – | – | – | – | 0.19i | 28 773 017 | 56j |
| Pooled (excl. Germany) | – | – | – | – | 0.20i | 17 735 114 | 35j |
IgAN, immunoglobulin A nephropathy.
See the ‘Reference populations’ subsection of the ‘Methods’ for sources.
Calculated as incidence × population.
Calculated as (number of IgAN cases/study duration)/reference population at the midpoint of the study period.
Number of pediatric patients with biopsy-confirmed primary glomerulopathy.
Germany data were from a single, internationally recognized teaching hospital.
No age range given in reference; definition assumed based on other studies.
Number of pediatric patients with biopsy-verified IgAN.
Number of pediatric patients with biopsy-verified IgAN over the full study period (1994–2013).
Calculated as sum of expected incident cases/sum of population.
The mean of the two Poland estimates was used (12 expected cases).
IgAN annual incidence and 2021 expected incident cases in pediatric patients in European countries, based on national kidney biopsy registry data (and regional data for Germany) (Estimate 2: pediatric patients).
| Country . | Registry . | Time frame . | Number of native kidney biopsies in pediatric patients . | Pediatric age group definition . | Annual IgAN incidence per 100 000 pediatric patients . | Pediatric population in 2021a . | Expected incident IgAN cases in pediatric patients in 2021b . |
|---|---|---|---|---|---|---|---|
| Croatia [32] | Registry of Biopsy-Proven Renal Diseases | 1991–2004 | 565 | 0–17 | 0.51c | 716 172 | 4 |
| Czech Republic [14] | Czech Registry of Renal Biopsies | 1994–2011 | 1421 | 0–15 | 0.78c | 1 721 898 | 13 |
| Estonia [16] | Tartu University Hospital | 2001–2010 | 13d | 0–15 | 0.00 | 209 330 | 0 |
| Germany [33] | University Hospital Aachen | 1990–2013 | 23 | 0–15 | 0.19c | 11 037 903 | 21e |
| Lithuania [18] | National Center of Pathology | 2007–2012 | 114 | 0–16f | 0.79c | 467 450 | 4 |
| Poland | |||||||
| [20] | Polish Registry of Renal Biopsies | 2009–2014 | 384 | 0–17 | 0.18c | 6 706 811 | 12 |
| [34] | Polish pediatric IgAN registry | 2000–2015 | 140g | 0–17 | 0.16 | 11 | |
| Spain [35] | Spanish Registry of Glomerulonephritis | 2010–2013 | 238h | 0–16 | 0.03c | 7 913 453 | 2 |
| Pooled (incl. Germany) | – | – | – | – | 0.19i | 28 773 017 | 56j |
| Pooled (excl. Germany) | – | – | – | – | 0.20i | 17 735 114 | 35j |
| Country . | Registry . | Time frame . | Number of native kidney biopsies in pediatric patients . | Pediatric age group definition . | Annual IgAN incidence per 100 000 pediatric patients . | Pediatric population in 2021a . | Expected incident IgAN cases in pediatric patients in 2021b . |
|---|---|---|---|---|---|---|---|
| Croatia [32] | Registry of Biopsy-Proven Renal Diseases | 1991–2004 | 565 | 0–17 | 0.51c | 716 172 | 4 |
| Czech Republic [14] | Czech Registry of Renal Biopsies | 1994–2011 | 1421 | 0–15 | 0.78c | 1 721 898 | 13 |
| Estonia [16] | Tartu University Hospital | 2001–2010 | 13d | 0–15 | 0.00 | 209 330 | 0 |
| Germany [33] | University Hospital Aachen | 1990–2013 | 23 | 0–15 | 0.19c | 11 037 903 | 21e |
| Lithuania [18] | National Center of Pathology | 2007–2012 | 114 | 0–16f | 0.79c | 467 450 | 4 |
| Poland | |||||||
| [20] | Polish Registry of Renal Biopsies | 2009–2014 | 384 | 0–17 | 0.18c | 6 706 811 | 12 |
| [34] | Polish pediatric IgAN registry | 2000–2015 | 140g | 0–17 | 0.16 | 11 | |
| Spain [35] | Spanish Registry of Glomerulonephritis | 2010–2013 | 238h | 0–16 | 0.03c | 7 913 453 | 2 |
| Pooled (incl. Germany) | – | – | – | – | 0.19i | 28 773 017 | 56j |
| Pooled (excl. Germany) | – | – | – | – | 0.20i | 17 735 114 | 35j |
IgAN, immunoglobulin A nephropathy.
See the ‘Reference populations’ subsection of the ‘Methods’ for sources.
Calculated as incidence × population.
Calculated as (number of IgAN cases/study duration)/reference population at the midpoint of the study period.
Number of pediatric patients with biopsy-confirmed primary glomerulopathy.
Germany data were from a single, internationally recognized teaching hospital.
No age range given in reference; definition assumed based on other studies.
Number of pediatric patients with biopsy-verified IgAN.
Number of pediatric patients with biopsy-verified IgAN over the full study period (1994–2013).
Calculated as sum of expected incident cases/sum of population.
The mean of the two Poland estimates was used (12 expected cases).
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
